IDAP: ANTIBODY TECHNOLOGY PLATFORM

Recognizing the need for improved monoclonal antibody therapeutics, Viventia Biotechnologies Inc. (“Viventia”), built a technology platform to discover and advance the next generation of anti-cancer monoclonal antibodies. Viventia’s proprietary discovery and development engine addresses the fundamental considerations in the advancement of antibody-based therapeutics:

1) choice of target;
2) method of generation;
3) mechanism of action; and
4) production

Immune Driven Antibody Platform (IDAP) Components

Fusogenics™
Captures the patient’s immune response to tumor associated antigens in a library format. Antibodies are screened in a functional assay using a semi-automated HTP process.

ImmunoMine™
A rapid screening ‘funnel’ built upon increasingly more rigorous tests designed to identify therapeutically promising tumor-specific antibodies.

Armed Antibodies™
Genetically engineered fusion proteins comprised of an antibody fragment and a potent tumor-activated cytotoxic protein (optimal safety and efficacy).

UnLock™
Isolation and identification of membrane-associated tumor markers. Serves as engine for identification of known and novel cell-surface targets. Has identified 14 new potential cancer drug targets and continues to discover new targets at a rate of one to two per quarter at the current scale.